According to filings with the U.S. Securities and Exchange Commission, Circle Pharma is raising up to $117,374,782.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, David Earp played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Circle Pharma
Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015. We recently raised Series B and Series C financing from The Column Group and NextTech Invest. We design and develop bioavailable macrocyclic peptide therapeutics against important clinical targets. We do this by applying a computational structure-based design approach that combines physics (conformational modeling), chemistry (innovative molecular components) and biology (protein target structure and function). We have selected intracellular protein-protein interactions that play key roles in cancer as the initial target group for our internal pipeline development. Circle is taking a new approach to the development of macrocylic peptide therapeutics that is based on the pioneering work of its founders to understand and computationally predict drug-like properties of macrocycles. Circle is advancing this understanding to design novel, inherently permeable macrocyclic peptide drug candidates against Circles internal targets and those of our collaboration partners.

To learn more about Circle Pharma, visit http://www.circlepharma.com/
Circle Pharma Linkedin Page: https://www.linkedin.com/company/circle-pharma-inc-/

Contact:
David Earp, President and Chief Executive Officer
650-392-0350
https://www.linkedin.com/in/david-j-earp-jd-phd-584ba03/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.